Our Investment Policy
Our Vision: Building the Future of Bioelectrical Medicine At AVB Biotechnology, our investment policy is rigorously focused on establishing the "Bioelectrical Epigenetic Programming" technology, developed via our Dr Biolyse® platform, as a new global standard. Our investment strategy is anchored on sustainable growth and the exportation of high-value-added technology.
Our Strategic Focus Areas
-
Global Regulatory Alignment: Progressing through the FDA and EMA clearance pathways in alignment with our 2026 strategic milestones, aiming to achieve top-tier registration under international medical device standards (MDR 2017/745).
-
Evidence-Driven Growth: Leveraging advanced biostatistical frameworks to translate our translational clinical and pre-clinical datasets—demonstrated across diverse mammalian species (human, companion, and livestock animals)—into robust academic and commercial value.
-
Intellectual Property and Innovation: Safeguarding our bioelectrical code repository and proprietary algorithms through global patents to engineer a comprehensive "platform technology" ecosystem that transcends standalone hardware.
-
Diversified Market Penetration: Optimizing cash flow and market share through products with rapid commercialization potential across human medicine, veterinary applications, and wearable health technologies.
Commitment to Value Creation: While spearheading a paradigm shift in the healthcare industry through our non-pharmacological, innovative therapeutic protocols characterized by a highly favorable biocompatibility and safety profile; we commit to generating long-term, sustainable value for our stakeholders through transparent governance, scientific ethics, and disciplined capital allocation.
Investor Relations Disclaimer: All statements contained herein that are not historical facts constitute "forward-looking statements" subject to significant risks and uncertainties. Our corporate objectives regarding regulatory clearings, final approvals of clinical trial outcomes, and market entry timelines may fluctuate based on decisions by global health authorities, the inherent nature of biomedical R&D, and macroeconomic dynamics. Investors are advised to evaluate the company's future projections considering these regulatory and operational variables.